Analytical Data
-
Gene name
CPS1/CPSase I
- Application
-
Alternative Names
Carbamoyl-phosphate synthase [ammonia], mitochondrial(EC 6.3.4.16)(Carbamoyl-phosphate synthetase I)(CPSase I)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8C196
-
Expression Region
551-743aa
-
Molecular Weight
26.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CPS1 (Carbamoyl-Phosphate Synthetase 1) is a crucial enzyme involved in the urea cycle, primarily responsible for the synthesis of carbamoyl phosphate from ammonia and bicarbonate, utilizing ATP. Deficiencies in CPS1 can lead to hyperammonemia, a severe condition characterized by elevated ammonia levels in the blood, resulting in neurological impairment and other serious health issues. Research on recombinant CPS1 protein has gained significant attention due to its potential therapeutic applications. By producing recombinant CPS1, researchers aim to understand the enzyme's structure-function relationship, catalytic mechanisms, and regulatory pathways. This understanding can enhance diagnostic tools for CPS1 deficiency and pave the way for novel therapeutic strategies, including enzyme replacement therapies or gene editing approaches. As a result, studies focused on the expression, purification, and characterization of CPS1 are critical for developing interventions to mitigate hyperammonemia's impact and improve patient outcomes. This research not only contributes to our understanding of metabolic disorders but also provides insights into potential wider applications in biotechnology and therapeutic enzyme engineering.
